Avenue Therapeutics Inc (OQ:ATXI)

Business Focus: Bio Therapeutic Drugs

Apr 24, 2024 07:30 am ET
Avenue Therapeutics Announces Reverse Stock Split
Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that it will effect a...
Mar 25, 2024 08:30 am ET
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that it will host a...
Mar 18, 2024 04:05 pm ET
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today reported financial results and...
Mar 15, 2024 08:15 am ET
Avenue Therapeutics Receives Positive Listing Determination from Nasdaq
Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that by decision dated...
Mar 11, 2024 08:00 am ET
Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting
Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Amy Chappell,...
Feb 22, 2024 08:30 am ET
Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy
Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the publication of...
Jan 16, 2024 08:40 am ET
Sidoti Events, LLC's Virtual January Micro-Cap Conference
NEW YORK, NY / ACCESSWIRE / January 16, 2024 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day January Micro-Cap Conference taking place Wednesday and Thursday, January 17-18, 2024. The presentation schedule is subject to change. Please visit www.sidoti.com/events for the most updated version and webinar links.
Jan 11, 2024 08:00 am ET
Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference
Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean,...
Jan 05, 2024 09:15 am ET
Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds
Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the entry into warrant...
Jan 04, 2024 08:30 am ET
Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol
Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that it has reached...
Jan 02, 2024 08:30 am ET
Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that all patients have...
Dec 01, 2023 08:30 am ET
Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting
Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Amy Chappell,...
Nov 13, 2023 04:05 pm ET
Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today reported financial results and...
Nov 02, 2023 03:00 pm ET
Avenue Therapeutics Announces Closing of $5.0 Million Public Offering
Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the closing of its...
Oct 31, 2023 09:15 am ET
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced the pricing of its...
Sep 05, 2023 08:30 am ET
Avenue Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean,...
Aug 14, 2023 04:01 pm ET
Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced...
Aug 10, 2023 04:15 pm ET
Avenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today reported financial results and...
Aug 01, 2023 08:30 am ET
Avenue Therapeutics Announces High Potency and Full Efficacy in a Model of Generalized Seizures for its Novel GABA-A Receptor Potentiator, BAER-101, Supporting Phase 2 Clinical Study
Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, announced today that BAER-101, the...
Jul 27, 2023 08:30 am ET
Avenue Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)
Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that the first patient...
Jul 25, 2023 08:30 am ET
Avenue Therapeutics Announces Agreement with the FDA on the Study Design and Analysis Approach of the Phase 3 Safety Study for IV Tramadol
Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that it has reached...
May 15, 2023 04:01 pm ET
Fortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced...
May 12, 2023 08:30 am ET
Avenue Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today reported financial results and...
Apr 27, 2023 08:30 am ET
Avenue Therapeutics to Present at Aegis Capital Virtual Conference
Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean,...
Apr 17, 2023 04:01 pm ET
Avenue Therapeutics Announces Regulatory Update Based on Type C Meeting with FDA and Next Steps in the Development of IV Tramadol
Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases, today announced that it has...
Mar 30, 2023 04:10 pm ET
Fortress Biotech Reports Record 2022 Financial Results and Recent Corporate Highlights
Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced...
Mar 30, 2023 04:01 pm ET
Avenue Therapeutics Reports Full Year 2022 Financial Results and Recent Corporate Highlights
Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases, today reported financial...
Mar 08, 2023 04:01 pm ET
Avenue Therapeutics Provides Regulatory Update on IV Tramadol and Other Corporate Updates
Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases, today announced that it will...
Mar 02, 2023 08:00 am ET
Avenue Therapeutics Enters into a Transformational License Agreement with AnnJi Pharmaceutical to Develop and Commercialize AJ201, a First-in-Class Clinical Asset for the Treatment of Spinal and Bulba
Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases, today announced that it has...
Jan 31, 2023 01:30 pm ET
Aegis Capital Corp. Acted as Exclusive Placement Agent on a $3.25 Million Registered Direct & Private Placement for Avenue Therapeutics, Inc. (NASDAQ:ATXI)
NEW YORK, NY / ACCESSWIRE / January 31, 2023 / Aegis Capital Corp. acted as Exclusive Placement Agent on a $3.25 Million Registered Direct & Private Placement for Avenue Therapeutics, Inc. (NASDAQ:ATXI).
Jan 31, 2023 01:09 pm ET
Avenue Therapeutics Announces Closing of $3.25 Million Registered Direct and Private Placement
Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases, today announced the closing...
Jan 27, 2023 11:58 am ET
Avenue Therapeutics Announces $3.25 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules
Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases, today announced that it has...
Jan 18, 2023 07:52 am ET
Thinking about buying stock in Ontrak, Avenue Therapeutics, Archer Aviation, Prenetics Global, or Oatly?
NEW YORK, Jan. 18, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OTRK, ATXI, ACHR, PRE, and OTLY.
Nov 10, 2022 04:10 pm ET
Avenue Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases (“CNS”), today reported...
Nov 08, 2022 08:30 am ET
Avenue Therapeutics Completes the Acquisition of Baergic Bio and its Selective GABA-A α2/3 Receptor Positive Allosteric Modulator for the Treatment of Central Nervous System Disorders
Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system (“CNS”) diseases, today announced the...
Oct 18, 2022 10:44 am ET
Thinking about buying stock in Zovio, Carnival Corp, Bank of America, Avenue Therapeutics, or Nio?
NEW YORK, Oct. 18, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ZVO, CCL, BAC, ATXI, and NIO.
Oct 17, 2022 11:51 am ET
Thinking about buying stock in Federated National, Acorda Therapeutics, Nio, Avenue Therapeutics, or Visa?
NEW YORK, Oct. 17, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FNHC, ACOR, NIO, ATXI, and V.
Oct 12, 2022 10:25 am ET
Aegis Capital Corp. Acted as Sole Bookrunner on a $12 Million Underwritten Public Offering for Avenue Therapeutics, Inc. (NASDAQ:ATXI)
NEW YORK, NY / ACCESSWIRE / October 12, 2022 / Aegis Capital Corp. acted as Sole Bookrunner on a $12 Million Underwritten Public Offering for Avenue Therapeutics, Inc. (NASDAQ:ATXI).
Oct 11, 2022 02:15 pm ET
Avenue Therapeutics Announces Closing of $12 Million Underwritten Public Offering
Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases, today announced the closing...
Oct 06, 2022 11:00 pm ET
Avenue Therapeutics Announces Pricing of $12 Million Underwritten Public Offering
Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases, today announced the pricing...
Oct 03, 2022 08:00 am ET
Urica Therapeutics Appoints Seasoned Biotech Executive Jay D. Kranzler, M.D., Ph.D., as Chairman and Chief Executive Officer
Urica Therapeutics, Inc. (“Urica” or the “Company”) (formerly known as UR-1 Therapeutics, Inc.), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary company focused on the development and commercialization of pharmaceutical products to...
Sep 27, 2022 10:56 am ET
Thinking about buying stock in AMC Entertainment, Faraday Future Intelligent Electric, Li Auto, Carvana, or Avenue Therapeutics?
NEW YORK, Sept. 27, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMC, FFIE, LI, CVNA, and ATXI.
Sep 23, 2022 10:50 am ET
Thinking about buying stock in Avenue Therapeutics, Color Star Technology, T2 Biosystems, NanoVibronix, or Energy Transfer?
NEW YORK, Sept. 23, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ATXI, CSCW, TTOO, NAOV, and ET.
Sep 22, 2022 04:25 pm ET
Avenue Therapeutics Announces Reverse Stock Split and Provides Regulatory Update for IV Tramadol Including Receipt of Type A Meeting Minutes from the FDA
Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases, today announced that it...
Mar 31, 2022 07:30 am ET
Abeona Therapeutics Announces Strategy Update and 2021 Financial Results
Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy, today provided a business and strategy update and reported 2021 financial results. “We are committed to developing novel cell and gene therapies for...
Feb 15, 2022 10:00 pm ET
Avenue Therapeutics Announces Outcome of FDA Advisory Committee Meeting on IV Tramadol
Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced the outcome of the U.S. Food and Drug Administration (“FDA”) joint meeting of the...
Feb 15, 2022 07:05 am ET
Avenue Therapeutics Stock Trading Halted Today
Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced that NASDAQ has halted trading of the Company’s common stock. The U.S. Food and Drug...
Dec 15, 2021 02:15 pm ET
Aegis Capital Corp. Acted as Sole Bookrunner on a $2 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ: ATXI)
NEW YORK, NY / ACCESSWIRE / December 15, 2021 / Aegis Capital Corp. acted as Sole Bookrunner on a $2 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ:ATXI).
Dec 15, 2021 12:00 pm ET
Avenue Therapeutics Announces Closing of Public Offering of Common Stock
Avenue Therapeutics, Inc. (or the “Company”) (NASDAQ: ATXI), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced the closing of its public offering of 1,910,100 shares of common stock at a public...
Dec 12, 2021 08:00 pm ET
Avenue Therapeutics Prices $2.0 Million Underwritten Public Offering of Common Stock
Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced the pricing of an underwritten public offering with gross proceeds to the Company expected...
Nov 29, 2021 08:00 am ET
Avenue Therapeutics Announces FDA Advisory Committee Meeting to Review IV Tramadol NDA Tentatively Scheduled for February 15, 2022
Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue” or the “Company”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced that the FDA has informed the Company that a joint meeting of the...
Nov 17, 2021 09:30 am ET
Avenue Therapeutics Announces Exercise and Closing of Underwriter’s Over-Allotment Option
Avenue Therapeutics, Inc. (the “Company”) (NASDAQ: ATXI), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced that the underwriter of its previously announced underwritten public offering has...
Nov 12, 2021 10:40 am ET
Aegis Capital Corp. acted as Sole Bookrunner on a $2.6 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ: ATXI)
NEW YORK, NY / ACCESSWIRE / November 12, 2021 / Aegis Capital Corp. acted as Sole Bookrunner on a $2.6 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ:ATXI).
Nov 12, 2021 09:20 am ET
Avenue Therapeutics Announces Closing of Public Offering of Common Stock
Avenue Therapeutics, Inc. (or the “Company”) (NASDAQ: ATXI), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced the closing of its public offering of 1,946,787 shares of common stock at a public...
Nov 09, 2021 09:30 pm ET
Avenue Therapeutics Prices $2.6 Million Underwritten Public Offering of Common Stock
Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced the pricing of an underwritten public offering with gross proceeds to the Company expected...
Oct 25, 2021 07:00 am ET
Avenue Therapeutics Receives Interim Response to its Formal Dispute Resolution Request from U.S. Food and Drug Administration Office of New Drugs
Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced that it has received a written interim response from the Office of New Drugs (“OND”) of...
Jun 14, 2021 07:00 am ET
Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol
Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced that it has received a second Complete Response Letter (“CRL”) from the U.S. Food and Drug...
Apr 23, 2021 11:36 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avenue Therapeutics, Inc. - ATXI
Pomerantz LLP is investigating claims on behalf of investors of Avenue Therapeutics Inc. (“Avenue” or the “Company”) (NASDAQ: ATXI). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....
Apr 14, 2021 10:34 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Avenue Therapeutics, Inc. - ATXI
Pomerantz LLP is investigating claims on behalf of investors of  Avenue Therapeutics Inc. (“Avenue” or the “Company”) (NASDAQ: ATXI). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980....
Apr 13, 2021 06:30 am ET
Avenue Therapeutics Announces that the FDA is Still Reviewing Its NDA Resubmission for IV Tramadol
Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced that the U.S. Food and Drug Administration (“FDA”) was still reviewing its New Drug...
Dec 18, 2020 08:00 am ET
Avenue Therapeutics Announces Publication of Real-World Data on Nonmedical Use of Tramadol in ASI-MV Network
Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today announced that a publication titled “Real-World Data on Nonmedical Use of Tramadol from Patients...
Dec 18, 2020 08:00 am ET
Avenue Therapeutics Announces Publication of Tramadol Non-Medical Use in Four European Countries: A Comparative Analysis
Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today announced that a publication titled “Tramadol Non-Medical Use in Four European Countries: A Comparative...
Dec 17, 2020 07:00 am ET
Avenue Therapeutics Provides Regulatory Update for IV Tramadol
Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today provided a regulatory update following receipt of the official meeting minutes from a November 2020 Type...
Oct 14, 2020 08:58 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avenue Therapeutics, Inc. - ATXI
NEW YORK, Oct. 14, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Avenue Therapeutics, Inc. ("Avenue Therapeutics" or the "Company") (NASDAQ: ATXI).  Such investors are advised to contact Robert S. Willoughby at  [email protected] or 888-476-6529, ext. 7980.
Oct 12, 2020 06:30 am ET
Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol
Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced it has received a Complete Response Letter (“CRL”) from the U.S. Food and Drug...
Sep 09, 2020 08:00 am ET
Avenue Therapeutics Announces Publication of a Review of IV Tramadol
Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced that a publication entitled “IV tramadol: A novel option for US patients with acute pain—A...
Aug 14, 2020 07:30 am ET
Avenue Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights
Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today reported financial results and recent corporate highlights for the second quarter ended June 30,...
Aug 12, 2020 07:30 am ET
Fortress Biotech Announces Virtual Two-Day Corporate Access Summit Hosted by B. Riley FBR on Tuesday, August 18 and Wednesday, August 19, 2020
Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today...
Jul 21, 2020 08:30 am ET
Avenue Therapeutics Announces Publication of Phase 3 Bunionectomy Study Results
Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced that the results from its Phase 3 study of IV tramadol in patients undergoing bunionectomy...
Jun 29, 2020 08:30 am ET
Fortress Biotech Added to Russell 3000® Index
Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing high-potential marketed pharmaceutical products and development-stage pharmaceutical product...
Jun 05, 2020 08:30 am ET
Avenue Therapeutics Announces Publications in Peer-Reviewed Journals
Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced the following publications in peer-reviewed journals. The publication titled “Intravenous...
May 29, 2020 08:30 am ET
Avenue Therapeutics to Host Virtual Annual Meeting of Stockholders
Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced that it will host the Company’s 2020 Annual Meeting of Stockholders (“Annual Meeting”)...
May 11, 2020 07:30 am ET
Avenue Therapeutics Reports First Quarter 2020 Financial Results and Recent Corporate Highlights
Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today reported financial results and recent corporate highlights for the first quarter ended March 31,...
Apr 23, 2020 08:30 am ET
Avenue Therapeutics Announces Presentation of IV Tramadol E-Posters
Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced that two e-posters highlighting efficacy and safety results from its Phase 3 program are...
Mar 30, 2020 07:30 am ET
Avenue Therapeutics Reports Full Year 2019 Financial Results and Recent Corporate Highlights
Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today reported financial results and recent corporate highlights for the year ended December 31, 2019....
Feb 13, 2020 08:00 am ET
Avenue Therapeutics Announces New Drug Application for IV Tramadol Accepted for Review by FDA
Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted for review Avenue’s New...
Dec 11, 2019 08:30 am ET
Avenue Therapeutics Announces Submission of New Drug Application for IV Tramadol
Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug...
Nov 04, 2019 07:30 am ET
Avenue Therapeutics Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights
Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today reported financial results and recent corporate highlights for the third quarter ended September 30,...
Oct 28, 2019 08:30 am ET
Avenue Therapeutics Announces Publication of IV Tramadol Phase 1 Clinical Data in Clinical Pharmacology in Drug Development
Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, announced today that its Phase 1 data on intravenous (IV) tramadol has been published in the peer-reviewed...
Oct 18, 2019 08:30 am ET
Avenue Therapeutics to Present Phase 3 Bunionectomy Study of IV Tramadol at the American Society of Anesthesiologists Annual Meeting
Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced an eAbstract presentation at ANESTHESIOLOGY® 2019, the Annual Meeting of the American...
Aug 14, 2019 07:30 am ET
Avenue Therapeutics Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights
Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today reported financial results and recent corporate highlights for the second quarter ended June 30,...
Aug 01, 2019 08:00 am ET
Avenue Therapeutics Announces Appointment of Ms. E. Garrett Ingram to Board of Directors
Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a specialty pharmaceutical company focused on the development and commercialization of intravenous (IV) tramadol, today announced that Ms. Garrett Ingram has been appointed to its Board of...
Jun 03, 2019 07:00 am ET
Avenue Therapeutics Announces Positive Topline Data from Second Pivotal Phase 3 Study of Intravenous Tramadol in the Management of Postoperative Pain
Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a specialty pharmaceutical company focused on the development and commercialization of intravenous (IV) tramadol, today announced that its second pivotal Phase 3 trial of IV tramadol achieved the...
May 13, 2019 07:30 am ET
Avenue Therapeutics Reports First Quarter 2019 Financial Results and Recent Corporate Highlights
Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today reported financial results and recent corporate highlights for the first quarter ended March 31,...
Apr 30, 2019 07:30 am ET
Avenue Therapeutics Announces Appointment of Dr. Thomas G. Moore to Board of Directors
Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a specialty pharmaceutical company focused on the development and commercialization of intravenous (IV) tramadol, today announced that Dr. Thomas G. Moore has been appointed to its Board of...
Mar 12, 2019 07:30 am ET
Avenue Therapeutics Reports Full Year 2018 Financial Results and Recent Corporate Highlights
Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today reported financial results and recent corporate highlights for the year ended December 31, 2018....
Feb 11, 2019 07:30 am ET
Avenue Therapeutics Announces First Stage Closing of its Acquisition Agreement with InvaGen (a Cipla subsidiary)
Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a Fortress Biotech (NASDAQ: FBIO) company, today announced the completion of the first stage closing of the Acquisition Agreement previously announced on November 13, 2018 with InvaGen...
Jan 19, 2019 06:45 pm ET
Stull, Stull & Brody Announces Class Action Suit on Behalf of Purchasers of the Securities of Avenue Therapeutics, Inc. (NasdaqCM: ATXI)
Stull, Stull & Brody (“SS&B”) announces that a class action lawsuit has been filed and it is investigating the Board of Directors of Avenue Therapeutics, Inc. ("Avenue" or the "Company") (NasdaqCM: ATXI) for possible breaches of fiduciary duty...
Dec 19, 2018 08:00 am ET
Avenue Therapeutics Announces Dosing of First Patient in Second Pivotal Phase 3 Clinical Trial of Intravenous Tramadol for the Management of Postoperative Pain
Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a specialty pharmaceutical company focused on the development and commercialization of intravenous (IV) tramadol, today announced that the first patient has been dosed in a pivotal Phase 3...
Dec 12, 2018 07:00 pm ET
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Avenue Therapeutics, Inc. - ATXI
NEW YORK, Dec. 12, 2018 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating the Board of Directors of Avenue Therapeutics, Inc. ("Avenue" or the "Company") (NasdaqCM: ATXI) for possible breaches of fiduciary duty related to the sale of the company to InvaGen Pharmaceuticals, Inc. and Madison Pharmaceuticals, Inc. Under the terms of the proposed transaction, Avenue shareholders are only anticipated to receive $13.92 for each share of Avenue comm
Nov 21, 2018 07:45 am ET
Research Report Identifies Chicken Soup for the Soul Entertainment, Allied Motion Technologies, Bandwidth, Solid Biosciences, Avenue Therapeutics, and BeyondSpring with Renewed Outlook — Fundamental A
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Chicken Soup for the Soul Entertainment, Inc. (NASDAQ:CSSE), Allied Motion...
Nov 14, 2018 04:30 pm ET
Avenue Therapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights
Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a specialty pharmaceutical company focused on the development and commercialization of intravenous (IV) tramadol, today reported financial results and recent corporate highlights for the third...
Nov 13, 2018 06:30 am ET
InvaGen (a Cipla subsidiary) Announces Acquisition Agreement with Avenue Therapeutics for Specialty Hospital Business in the U.S.
InvaGen Pharmaceuticals Inc. (“InvaGen”), a subsidiary of the leading global pharmaceutical company Cipla Limited, today announced that it has entered into definitive agreements with two closing stages for a proposed acquisition of Avenue...
Aug 14, 2018 07:30 am ET
Avenue Therapeutics Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights
Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a specialty pharmaceutical company focused on the development and commercialization of intravenous (IV) tramadol, today reported financial results and recent corporate highlights for the second...
Jun 19, 2018 08:30 am ET
Avenue Therapeutics to Participate in JMP Securities Life Sciences Conference
Avenue Therapeutics, Inc. (Nasdaq:ATXI) (“Avenue”), a specialty pharmaceutical company focused on the development and commercialization of intravenous (IV) tramadol, today announced that Lucy Lu, M.D., President and Chief Executive Officer, will...
Jun 06, 2018 08:30 am ET
Avenue Therapeutics to Host Key Opinion Leader Call on Intravenous (IV) Tramadol for the Management of Postoperative Pain
Avenue Therapeutics, Inc. (Nasdaq:ATXI) (“Avenue”), a company focused on the development and commercialization of intravenous (IV) tramadol, today announced that it will host a Key Opinion Leader (KOL) call on intravenous (IV) tramadol for the...
May 21, 2018 06:30 am ET
Avenue Therapeutics Announces Positive Topline Phase 3 Data for Intravenous Tramadol in the Management of Postoperative Pain
Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a company focused on the development and commercialization of intravenous (IV) tramadol, today announced that its first pivotal Phase 3 trial of IV tramadol achieved the primary endpoint of a...
May 03, 2018 07:30 am ET
Avenue Therapeutics Reports First Quarter 2018 Financial Results and Recent Corporate Highlights
Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a company focused on the development and commercialization of intravenous (IV) tramadol, today reported financial results and recent corporate highlights for the first quarter ended March 31,...
Mar 28, 2018 08:00 am ET
Avenue Therapeutics Receives Notices of Allowance for Patent Applications Covering Methods of Administration for Intravenous Tramadol
NEW YORK, March 28, 2018 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a company focused on the development and commercialization of intravenous (IV) tramadol, today announced receipt of Notices of Allowance from the U.S. Patent and Trademark...
Mar 05, 2018 08:00 am ET
Avenue Therapeutics to Present at March Investor Conferences
NEW YORK, March 05, 2018 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a company focused on the development and commercialization of intravenous (IV) tramadol, today announced that Lucy Lu, M.D., Avenue’s President and Chief Executive Officer, will...
Mar 01, 2018 07:30 am ET
Avenue Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Corporate Highlights
-- Expect to Report Topline Data from Phase 3 Trial of IV Tramadol in Patients Following Bunionectomy Surgery in 2Q18 --
Feb 09, 2018 10:00 am ET
Feb 06, 2018 08:30 am ET
Avenue Therapeutics to Participate in Panel on Opioid Abuse at BIO CEO & Investor Conference
NEW YORK, Feb. 06, 2018 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a company focused on the development and commercialization of intravenous (IV) tramadol, today announced that Lucy Lu, M.D., Avenue’s President and Chief Executive Officer, will...
Jan 02, 2018 08:00 am ET
Avenue Therapeutics Announces Dosing of First Patient in Phase 3 Safety Trial of Intravenous Tramadol for the Management of Postoperative Pain
NEW YORK, Jan. 02, 2018 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a company focused on the development and commercialization of intravenous (IV) tramadol, today announced that it has dosed the first patient in its Phase 3...
Nov 09, 2017 07:30 am ET
Avenue Therapeutics Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights
NEW YORK, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a Fortress Biotech (NASDAQ:FBIO) Company, today announced financial results and recent corporate highlights for the third quarter ended September 30, 2017.
Aug 11, 2017 07:30 am ET
Avenue Therapeutics Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights
NEW YORK, Aug. 11, 2017 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ:ATXI) (“Avenue”), a Fortress Biotech (NASDAQ:FBIO) Company, today announced financial results and recent corporate highlights for the second quarter ended June 30, 2017....

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.